Vaccine Market – Market Outlook & Trends
The global Vaccine Market was estimated to be USD 42.7 billion in 2019, and it might reach USD 89.7 billion by 2026, at a CAGR of 11.2%, over the projection period. The high occurrence rate of infectious diseases and other chronic conditions in the country, the growing aging population base, and many initiatives taken by the governments to expand vaccines' provision in the nations will positively influence business development.
Moreover, the growth of new and improved immunizations for several diseases is a significant factor in predicting growth. The occurrence of several pipeline drugs might lead to the development of the Vaccine Market.
The surge in the occurrence of infectious diseases in France, including measles, has stimulated the demand for vaccines in the country after high CAGR during the forecast period. Furthermore, many labors assumed by the French health bodies to make mindfulness about vaccines through social media platforms, including LinkedIn, Facebook, Twitter, have motivated the acceptance of vaccines in France.
Vaccine Market – Overview
Vaccines, also known as immunizations, vaccinate a debilitating form of illness into a person, so the body starts creating antibodies or protection. Simple vaccination has eliminated several conditions, like polio and smallpox, responsible for high death rates. The U.S. Food and Drug Administration newly permitted the first vaccine for dengue disease, the foremost cause of illness among people living in the tropics and subtropics. Vaccines can also be used as a therapeutic after contamination occurs. This kind of action has lately developed prevalent in immune-oncology for cancer, making up 15 percent of immunotherapies in 2014. The vaccine market lasts to show development, although the anti-vaccine movement. This drive has created an atmosphere of suspicion around vaccines in the U.S., despite growing indications of vaccines' safety and efficacy. The World Health Organization has named vaccine hesitancy as one of the top ten threats fronting public health this year.
in the incidence of both viral and bacterial infectious diseases
An escalation in communicable diseases universal, including Ebola, influenza, swine flu, hepatitis, tuberculosis, diphtheria, and meningococcal and pneumococcal diseases. These are one of the chief drivers of market growth. Treatments are practically administered to people of different age groups, strengthening their resistant system during a lifetime. Treatments offer protection against dissimilar types of infectious diseases—besides, emerging vaccines (Zika vaccines, dengue vaccines, cancer vaccines, and others), making of technologically advanced vaccines, advancements in vaccine delivery devices, and the increase in immunization programs, besides market growth.
Healthy Supply backed up by Robust R&D to drive the Vaccines Market
One of the vital and noteworthy drivers for market growth is the growing source of vaccines crosswise the sphere to meet the unmet needs and abide by the immunization policies to eradicate widespread diseases. Pharmaceutical companies, government foundations, international organizations, and hospitals are strongly absorbed in providing cost-effective and regular vaccination to people universal. A government investigation in all the countries has become active in safeguarding that suggested Vaccines at a minimum cost or no cost vaccinate every individual.
Vaccine Market: Segmentation
The pediatric patient's section accounted for the larger share of the vaccines market, by patient type. Based on patient type, the vaccine market falls into pediatric and adult patients. The pediatric patient's section accounted for the central part of the global vaccines market in 2018. This situation can be accredited to the growing government initiatives for immunization and the rising occurrence of illnesses.
By technology, the conjugate vaccines section accounted for the leading market share in 2018. The vaccines market falls into conjugate vaccines, inactivated, and subunit vaccines live lessened vaccines, recombinant vaccines, and toxoid vaccines based on technology. In 2018, the conjugate vaccines segment accounted for the leading share of the vaccines market. This section's large percentage goes to increasing government support and rising company investments in conjugate vaccine growth.
The Intramuscular & subcutaneous administration section is expected to see the uppermost development during the prediction period. Based on the route of administration, the vaccine market falls into intramuscular and subcutaneous administration, oral administration, and other ways of administration. The subcutaneous administration and intramuscular segment accounted for the central portion of the global vaccines market in 2018 and is probable to list the highest CAGR during the estimated period.
Geographically, The Global Vaccine Market falls into North America, Europe, Asia Pacific, South America, and the Middle East & Africa. The Asia Pacific region is predictable to bystander the firmest development over the prediction period, credited by the rising target people base with high-unmet clinical needs. Also, the growing disposable income level and the increasing mindfulness regarding the merits of vaccination in the Asia Pacific region's emerging economies are further predictable to foster market development.
Vaccine Market: Regional Insights
North America accounted for a significant portion of the vaccine market in 2018. The large share of North America in the global vaccines market is credited to the high occurrence of infectious diseases and growing savings by government and non-government organizations for vaccine development. On the other hand, Asia's market is predicted to register the highest growth during the prediction period. Factors such as the growing healthcare spending and disposable income, government initiatives, and the occurrence of a large patient people are inducing the growth of the vaccine market in Asia.
The key players in the market include GlaxoSmithKline plc. (U.K.), Pfizer, Inc. (U.S.), Merck & Co., Inc. (the U.S.), and Sanofi Pasteur SA (France) CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), Johnson & Johnson (U.S.), Serum Institute of India (India), AstraZeneca (U.K.), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), and Daiichi Sankyo Company, Limited (Japan), and others.
July 2019, the International Finance Facility for Immunization (IFFIm) issued
NOK600 million vaccine bonds to assist in financing the research and
development of new vaccines by Coalition for Epidemic Preparedness Innovation
June 2019, Bharat Biotech collaborated with a research firm, namely, Hilleman Labs, to advance the cholera vaccine's phase three development. The strategy aimed at filling the supply gap created due to the elevated incidence of the disease, especially in South Asian countries and the Sub-Sahara region. Nearly 21,000 to 143,000 people die due to cholera annually, leading to escalated demand, hence fueling the cholera vaccine industry's growth.
of the Report
East & Africa
The objective of the Study:
Ø To analyze and estimate the Global Vaccine Market size in terms of value.
Ø To sift through the market segmentation and estimate the market size, in terms of value, based on the region by segmenting the Global Vaccine Market into five areas, namely, North America, Europe, Asia Pacific, Rest of the World, and their leading countries.
Ø To outline, categorize, and project the Global Vaccine Market-based on Technology, Disease, Patient Population, Route of Administration, and Region.
Ø To examine competitive developments in Technology, Disease, Patient Population, Route used for administration across different age-groups within the Global Vaccine Market.
Ø To provide a detailed competitive landscape, including major players, their strategic profiles, and market shares.
Business Questions Answered by the Report:
Ø How will the market drivers, restraints, and opportunities affect the market dynamics?
Ø What will be the market size in terms of value and volume and market statistics with a detailed classification?
Ø Which segment dominates the market or region, and which one will be the fastest-growing, and why?
Ø Who are the key players in the market, and what is their share?
Ø What is the strategy adopted by key players, and how does it affect the existing and new players?
Customization Scope for the Client:
Client satisfaction is our first and last priority, and that is why BlueWeave Consulting offers customization as per the client's specific needs. The following customization options are available for the report:
Ø Additional Company Information
Ø Detail Analysis of five additional companies
Ø Additional country analysis
Detailed segment analysis
Historical data – 2016-2018
Base Year – 2019
Forecast – 2020 – 2026
Revenue in USD Billion
Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico, Japan, South
Korea, China, India, South Korea UAE, South Africa, Saudi Arabia.
By Disease, By Route, By Patient, By
GlaxoSmithKline plc. (U.K.), Pfizer, Inc. (U.S.), Merck & Co., Inc. (the U.S.), and Sanofi Pasteur SA (France) CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), Johnson & Johnson (U.S.), Serum Institute of India (India), AstraZeneca (U.K.), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), and Daiichi Sankyo Company, Limited (Japan) and others.